Marelys Torres Abreu, APRN
Payments from drug & device makers
Across 544 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Ardelyx, Inc.$564
- QOL Medical, LLC$511
- Takeda Pharmaceuticals U.S.A., Inc.$410
- plus $4K from 27 others
What the payments were for
- Food & beverage$10,77595%
- Education$5805%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 114 | $2,800 |
| Johnson & Johnson(2 entities) | 62 | $1,717 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 127 | $1,578 |
| Ardelyx, Inc. | 36 | $564 |
| QOL Medical, LLC | 32 | $511 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $410 |
| Madrigal Pharmaceuticals | 16 | $305 |
| Phathom Pharmaceuticals, Inc. | 10 | $268 |
| Redhill Biopharma Inc. | 23 | $265 |
| Aimmune Therapeutics, Inc. | 7 | $255 |
| Braintree Laboratories, Inc. | 12 | $250 |
| Intercept Pharmaceuticals, Inc. | 11 | $243 |
| Celltrion USA Inc. | 6 | $235 |
| Evoke Pharma, Inc. | 13 | $233 |
| Nestle Healthcare Nutrition Inc. | 13 | $224 |
| E.r. Squibb & Sons, L.L.C. | 2 | $216 |
| Gilead | 4 | $181 |
| Medtronic | 1 | $170 |
| Bristol Myers Squibb | 6 | $123 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 4 | $107 |
| Ironwood Pharmaceuticals, Inc | 5 | $98 |
| Sanofi | 3 | $85 |
| Merck | 4 | $79 |
| Lilly USA, LLC | 3 | $59 |
| Novo Nordisk | 2 | $53 |
| Ipsen Biopharmaceuticals, Inc | 2 | $44 |
| Exact Sciences | 2 | $41 |
| Vivus LLC | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Biocon Biologics Inc | 1 | $24 |
| Pfizer | 1 | $21 |
| Organon | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,355 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 73 | $186,420 |
| LinzessLinaclotide | 197 | $186,094 |
| ZenpepLipase/Protease/Amylase | 39 | $135,257 |
| RezdiffraResmetirom | 34 | $134,042 |
| XifaxanRifaximin | 43 | $128,520 |
| OzempicSemaglutide | 71 | $73,676 |
| Dexlansoprazole DrDexlansoprazole | 124 | $30,146 |
| IbsrelaTenapanor Hcl | 15 | $25,401 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 112 | $19,175 |
| TrulancePlecanatide | 22 | $16,157 |
| Mesalamine | 37 | $15,282 |
| MounjaroTirzepatide | 14 | $15,035 |
| MotegrityPrucalopride Succinate | 18 | $13,579 |
| Sucralfate | 62 | $13,017 |
| Famotidine | 689 | $8,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,800 | $372,515270 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $1,578 | $146,32277 claims |
| Aimmune Therapeutics, Inc.Zenpep | $255 | $135,25739 claims |
| Madrigal PharmaceuticalsRezdiffra | $305 | $134,04234 claims |
| Novo NordiskOzempic | $53 | $73,67671 claims |
| Ardelyx, Inc.Ibsrela | $564 | $25,40115 claims |
| Lilly USA, LLCMounjaro | $59 | $15,03514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $410 | $13,57918 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $250 | $8,56762 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.